This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should BNY Mellon US Mid Cap Core Equity ETF (BKMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for BKMC
Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?
by Zacks Equity Research
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day.
Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs
by Zacks Equity Research
AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
by Zacks Equity Research
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.
Should iShares Morningstar Mid-Cap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study
by Zacks Equity Research
Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
by Zacks Equity Research
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.